H.B. Fuller Company has announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for £715 million, aiming to expand its presence in high-growth medical segments and accelerate its path to achieving greater than 20% EBITDA margins. The transaction, which values the target at a pre-synergy EBITDA multiple of 12.9x, is expected to close by the end of the calendar year subject to regulatory approvals. H.B. Fuller shares traded lower in Thursday’s premarket session as investors weighed the offer alongside second-quarter results that beat estimates and raised guidance.

Strategic Rationale

The acquisition is designed to extend H.B. Fuller’s capabilities in tissue bonding adhesives, tapes, dressings, and formulated biosurgicals. By integrating Advanced Medical Solutions, the company anticipates its total addressable market will increase by $15 billion to $95 billion. The deal is also expected to drive immediate cross-selling opportunities through Advanced Medical Solutions’ pan-European salesforce and H.B. Fuller’s U.S. infrastructure.

Financial Synergies and Margins

H.B. Fuller projects the transaction will generate approximately $55 million, or £41 million, in combined run-rate revenue and cost synergies by 2031. These synergies will stem from the elimination of public company costs, rationalization of overlapping expenses, and sourcing savings. The company also expects the acquisition to increase annual revenues by approximately $300 million and contribute to a positive mix shift, supporting its long-term target of 5% annual constant currency revenue growth.

Transaction Structure

Each eligible shareholder of Advanced Medical Solutions will receive £2.85 per share in cash. The acquisition will be fully financed through 100% committed financing. H.B. Fuller intends to rapidly deleverage to a target net debt-to-EBITDA ratio of 2.5x to 3x within two years of the transaction's completion. The deal will establish a new global business unit accounting for approximately 10% of the combined company’s revenues and EBITDA.

Q2 FY26 Performance

H.B. Fuller reported net revenue of $950.3 million for the second quarter of fiscal 2026, an increase of 5.8% year-over-year, surpassing the $924.8 million estimate. Organic revenue grew 2.6%, with pricing gains offsetting a slight decline in volume. Net income reached $68 million. Adjusted EBITDA rose 9% to $181 million, and adjusted diluted EPS increased 19% to $1.41, exceeding the $1.40 estimate. Adjusted gross margin improved by 200 basis points to 34.2%, primarily due to effective pricing and restructuring savings.

Cash Flow, Debt, and Guidance

Operating cash flow reached a record $121 million for the second quarter, up approximately 10% year-over-year. The company also repurchased 750,000 shares during the quarter. H.B. Fuller ended the quarter with cash and cash equivalents of $114.10 million. Net debt was $1.958 billion, down $58 million year-on-year, while net debt-to-adjusted EBITDA improved to 3.1x from 3.4x. For fiscal 2026, the company raised its adjusted EPS guidance to $4.60–$4.90 from $4.55–$4.90.

Key Transaction Metrics

Integration and Operational Benefits

The combined entity will leverage Advanced Medical Solutions’ dedicated R&D team of over 75 individuals and its manufacturing base across the UK, Germany, France, the Netherlands, Thailand, and India. H.B. Fuller highlighted its track record of mergers and acquisitions, noting that since 2023, it has acquired and integrated 11 companies, resulting in a 55% increase in EBITDA and an expansion of EBITDA margins by over 1,000 basis points across that portfolio.

H.B. Fuller Company reported second quarter fiscal 2026 financial results for the period ended May 30, 2026, delivering strong year-on-year growth across revenue, earnings, and cash flow. The world's largest pure-play adhesives company posted net revenue of $950.271 million, surpassing the analyst consensus estimate of $924.792 million and representing a 5.81% increase over $898.095 million in the prior year period. Adjusted earnings per share (diluted) came in at $1.41, up 19% year-on-year and ahead of the analyst consensus estimate of $1.40. Reported EPS (diluted) was $1.23. The company also achieved record second quarter operating cash flow of $121 million, up approximately 10% year-on-year.

Key Second Quarter Financial Highlights

The following table summarizes H.B. Fuller's key financial metrics for the second quarter:

Organic revenue increased 2.6% year-on-year, driven by a 3.0% pricing increase that more than offset slightly lower volume of (0.4)%. Foreign currency translation and acquisitions contributed 3.1% and 0.1% to net revenue growth, respectively. Selling, general and administrative (SG&A) expense was $202.365 million, with adjusted SG&A of $196.498 million, up 11% year-on-year. Adjusted SG&A, excluding foreign exchange and variable compensation impacts, was up approximately 3% year-on-year.

Segment Performance

H.B. Fuller operates through three segments. The table below presents segment net revenue and adjusted EBITDA for the second quarter:

Balance Sheet and Working Capital

Net debt at the end of the second quarter of fiscal 2026 was $1,958 million, down $58 million year-on-year. Net debt-to-adjusted EBITDA stood at 3.1X, an improvement from 3.4X at the end of the second quarter of fiscal 2025. Net working capital as a percentage of annualized net revenue was 16.4%, a sequential decrease of 260 basis points versus the first quarter. Total assets as of May 30, 2026 were $5,328.793 million, compared to $5,182.706 million as of November 29, 2025.

Management Commentary

Celeste Mastin, president and chief executive officer, commented: "We executed very well in the second quarter, delivering strong year-on-year revenue, EBITDA, and EPS growth, with results above the midpoint of our EBITDA guidance range. Our global sourcing capabilities and swift pricing actions have enabled us to maintain supply continuity and reliably serve our customers through market disruption. These efforts, combined with our Quantum Leap restructuring initiative, have strengthened our competitive position and we remain confident in our ability to deliver strong financial results."

Mastin added: "While the external environment remains dynamic, our focus is clear: we are executing on what we can control, leveraging our competitive strengths, and continuing to build a business that is more durable and better positioned to deliver superior long-term growth."

Fiscal 2026 Guidance

Based on year-to-date performance, H.B. Fuller raised the midpoint of its full-year adjusted EBITDA and adjusted EPS guidance. The updated fiscal 2026 outlook is summarized below:

The updated adjusted EPS guidance range of $4.60–$4.90 compares to the analyst consensus estimate of $4.84 and the previously communicated range of $4.55–$4.90. On April 16, H.B. Fuller also increased its quarterly dividend by 4.3%.

Analyst Ratings and Price Targets

Several Wall Street analysts have recently revised their outlooks on the stock. The table below summarizes recent analyst actions:

UBS analyst Lucas Beaumont maintained a Neutral rating while raising the price target to $71 from $63. JP Morgan analyst Jeffrey Zekauskas upgraded the stock from Underweight to Neutral with a price target of $58 on May 27, 2026. Citigroup analyst Patrick Cunningham maintained a Buy rating and raised the price target from $67 to $70 on March 30, 2026. Seaport Global analyst Michael Harrison upgraded the stock from Neutral to Buy with a price target of $80 on Sept. 26, 2025. Baird analyst Ghansham Panjabi maintained an Outperform rating and boosted the price target from $60 to $75 on June 27, 2025.